Mili Jyotsna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mili Jyotsna has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abhijit R. Rozatkar
Department of Psychiatry, All India Institute of Medical Sciences, Bhopal, India
1 shared publication Achukatla Kumar
Department of Cardiology, Nizam Institute of Medical Sciences, Hyderabad, Telangana, India
1 shared publication- Ananyan Sampath
Medicine, All India Institute of Medical Sciences, Bhopal, Bhopal, IND
1 shared publication - Anayansi Lasso-Pirot
Division of Pediatric Pulmonology, Allergy and Sleep Medicine University of Maryland School of Medicine Baltimore Maryland USA
1 shared publication - Arwa Bohra
Division of Hematology, Mayo Clinic, Rochester, MN, USA
1 shared publication - Keslar Just
Division of Pediatric Pulmonology, Allergy and Sleep Medicine University of Maryland School of Medicine Baltimore Maryland USA
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (5) , 874-878
Beyond the Wheeze: Incidental Diagnosis of Eosinophilic Oesophagitis in a Young Child With Asthma‐Like Symptoms
- 20 March 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (5) , 874-878
Open AccessBeyond the Wheeze: Incidental Diagnosis of Eosinophilic Oesophagitis in a Young Child With Asthma‐Like Symptoms
- Open Access
- 9 September 2024
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 46 (5) , 417-424
Training Needs Analysis for Medical Students in Assessing Cognitive Functioning: An Observational Study
Backgrounds: Research shows that medical students’ knowledge and skills concerning the assessment of cognition in various neuropsychiatric conditions (e.g., Alzheimer’s disease and schizophrenia) are unsatisfactory. This research aims to conduct a training needs analysis (TNA) for medical students to identify and refer patients with neuropsychiatric conditions. Methods: The study comprised two phases. First, developing a TNA toolkit to assess training needs in clinical tasks related to cognitive function assessment (by adopting the Hennessy–Hicks TNA toolkit); and second, through a self-reported survey, their training needs in cognitive function assessment were assessed. Data analysis involved calculating training gaps, importance scores, performance scores, training scores, and organization scores for various clinical tasks-stratified participants’ study year; for training needs and trends, factor analysis and post-hoc analyses were conducted. Results: A total of 153 medical students from a tertiary care center participated in the survey. The participants rated their performance lower than the perceived importance of tasks, indicating a need for improvement in all competencies ( P < .01). Pre–final-year students had the highest training needs, particularly in accessing literature, planning, and organizing care for patients with cognitive impairment, performing mental status examination, screening patients for cognitive deficits, and counseling them/caregivers about interventions ( P < .01). Factor analysis identified a single dominant factor, suggesting a correlation among these skills. Conclusion: Pre–final-year students require targeted training, whereas students beyond this stage can benefit from special training modules and awareness of available resources for cognitive assessment. The findings also suggest the importance of a hybrid approach involving training and organizational modifications.
- 9 September 2024
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 46 (5) , 417-424
Open AccessTraining Needs Analysis for Medical Students in Assessing Cognitive Functioning: An Observational Study
Backgrounds: Research shows that medical students’ knowledge and skills concerning the assessment of cognition in various neuropsychiatric conditions (e.g., Alzheimer’s disease and schizophrenia) are unsatisfactory. This research aims to conduct a training needs analysis (TNA) for medical students to identify and refer patients with neuropsychiatric conditions. Methods: The study comprised two phases. First, developing a TNA toolkit to assess training needs in clinical tasks related to cognitive function assessment (by adopting the Hennessy–Hicks TNA toolkit); and second, through a self-reported survey, their training needs in cognitive function assessment were assessed. Data analysis involved calculating training gaps, importance scores, performance scores, training scores, and organization scores for various clinical tasks-stratified participants’ study year; for training needs and trends, factor analysis and post-hoc analyses were conducted. Results: A total of 153 medical students from a tertiary care center participated in the survey. The participants rated their performance lower than the perceived importance of tasks, indicating a need for improvement in all competencies ( P < .01). Pre–final-year students had the highest training needs, particularly in accessing literature, planning, and organizing care for patients with cognitive impairment, performing mental status examination, screening patients for cognitive deficits, and counseling them/caregivers about interventions ( P < .01). Factor analysis identified a single dominant factor, suggesting a correlation among these skills. Conclusion: Pre–final-year students require targeted training, whereas students beyond this stage can benefit from special training modules and awareness of available resources for cognitive assessment. The findings also suggest the importance of a hybrid approach involving training and organizational modifications.
- Open Access
- 9 February 2022
- Published by Scientific Scholar in Indian Journal of Cardiovascular Disease in Women
- Vol. 06, 230-234
Incidence of Cardiovascular Events and Mortality in COVID-19 Patients Admitted in NIMS Intensive Care Unit during Second Wave
Prevalence of pulmonary thromboembolism (PTE) is very high when we compare the coronavirus disease 2019 positive patients with the other patients who are admitted in intensive care unit for other different infection. Thorough evaluation of the different causative factors for PTE should be better evaluated and prevention can be tried accordingly. Incidence of subclinical PTE that can give rise to future cardiac disease needs to be studied and plan of action can be done accordingly. Newer modalities of detecting PTE using non-invasive or simple invasive techniques need to be investigated to cope up in pandemic situation. Publication Date: 09 February 2022 (online) © 2022. Women in Cardiology and Related Sciences. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 9 February 2022
- Published by Scientific Scholar in Indian Journal of Cardiovascular Disease in Women
- Vol. 06, 230-234
Open AccessIncidence of Cardiovascular Events and Mortality in COVID-19 Patients Admitted in NIMS Intensive Care Unit during Second Wave
Prevalence of pulmonary thromboembolism (PTE) is very high when we compare the coronavirus disease 2019 positive patients with the other patients who are admitted in intensive care unit for other different infection. Thorough evaluation of the different causative factors for PTE should be better evaluated and prevention can be tried accordingly. Incidence of subclinical PTE that can give rise to future cardiac disease needs to be studied and plan of action can be done accordingly. Newer modalities of detecting PTE using non-invasive or simple invasive techniques need to be investigated to cope up in pandemic situation. Publication Date: 09 February 2022 (online) © 2022. Women in Cardiology and Related Sciences. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- Open Access
- 14 September 2020
- Published by Scientific Scholar in Indian Journal of Cardiovascular Disease in Women
- Vol. 5 (03) , 216-222
Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
Coronaviruses are a large family of single positive-stranded, enveloped RNA viruses that can infect many animal species and humans. Human coronaviruses can be divided based on their pathogenicity. Globally so far, over nine million people have tested COVID-19 positive, of which, 4, 25,000 are in India. The FDA for the prevention or treatment of COVID-19 has approved no drugs or biologics. Numerous other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as potential therapies. Searching for effective therapies for COVID-19 infection is a complex process. The cardiovascular disease (CVD) drugs and the COVID-19 treating drugs show potent drug–drug interactions (DDI), disease–drug interactions, and disease–disease interactions.
- 14 September 2020
- Published by Scientific Scholar in Indian Journal of Cardiovascular Disease in Women
- Vol. 5 (03) , 216-222
Open AccessDrug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
Coronaviruses are a large family of single positive-stranded, enveloped RNA viruses that can infect many animal species and humans. Human coronaviruses can be divided based on their pathogenicity. Globally so far, over nine million people have tested COVID-19 positive, of which, 4, 25,000 are in India. The FDA for the prevention or treatment of COVID-19 has approved no drugs or biologics. Numerous other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as potential therapies. Searching for effective therapies for COVID-19 infection is a complex process. The cardiovascular disease (CVD) drugs and the COVID-19 treating drugs show potent drug–drug interactions (DDI), disease–drug interactions, and disease–disease interactions.